Keebeck Wealth Management bought a new stake in Palomar Holdings, Inc. (NASDAQ:PLMR – Free Report) during the second quarter, Holdings Channel.com reports. The firm bought 4,809 shares of the company’s stock, valued at approximately $608,000.
Several other hedge funds and other institutional investors also recently modified their holdings of the company. Geneos Wealth Management Inc. bought a new position in shares of Palomar during the fourth quarter worth about $32,000. Kestra Advisory Services LLC bought a new stake in Palomar in the 4th quarter valued at about $33,000. Rockefeller Capital Management L.P. lifted its position in Palomar by 81.5% in the 4th quarter. Rockefeller Capital Management L.P. now owns 294 shares of the company’s stock valued at $40,000 after purchasing an additional 132 shares during the last quarter. Frazier Financial Advisors LLC acquired a new position in Palomar during the 2nd quarter valued at about $51,000. Finally, Parallel Advisors LLC boosted its stake in Palomar by 638.3% during the 1st quarter. Parallel Advisors LLC now owns 443 shares of the company’s stock valued at $53,000 after purchasing an additional 383 shares during the period. Institutional investors and hedge funds own 90.25% of the company’s stock.
Palomar News Roundup
Here are the key news stories impacting Palomar this week:
- Positive Sentiment: Strong premium growth and expansion in specialty insurance are expected to support Palomar’s earnings momentum. Analysts’ average price target of $162.75 and recent target increases reinforce the bullish view. Can Strong Premium Growth Sustain Palomar’s Earnings Momentum?
- Positive Sentiment: Dowling & Partners expressed a positive view of Palomar’s fiscal 2026 earnings outlook, adding to expectations for continued profit growth. DOWLING & PARTN Has Positive View of Palomar FY2026 Earnings
- Positive Sentiment: Palomar’s latest quarterly results provide fundamental support: earnings per share of $2.36 exceeded the $2.19 consensus estimate, while profitability and return on equity remained strong.
- Neutral Sentiment: Several insiders, including the president, CFO and Jonathan Knutzen, sold relatively small portions of their holdings to cover tax withholding on vested equity awards. Because the transactions were not discretionary sales, they are less negative than typical insider selling, though they may limit near-term sentiment.
- Neutral Sentiment: Palomar declared a quarterly dividend of $0.45, equivalent to $1.80 annually and a yield of approximately 1.4%, providing modest shareholder support.
- Negative Sentiment: Competitive pricing could reduce premium profitability, while a higher combined ratio would pressure underwriting margins. These risks may temper the market’s response to otherwise strong growth expectations. Can Strong Premium Growth Sustain Palomar’s Earnings Momentum?
Analysts Set New Price Targets
View Our Latest Stock Report on Palomar
Insider Transactions at Palomar
In other news, CFO T Christopher Uchida sold 791 shares of Palomar stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $127.74, for a total transaction of $101,042.34. Following the transaction, the chief financial officer directly owned 16,238 shares in the company, valued at approximately $2,074,242.12. This trade represents a 4.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Rodolphe Herve sold 1,207 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $135.35, for a total value of $163,367.45. Following the completion of the sale, the chief operating officer directly owned 3,548 shares in the company, valued at $480,221.80. This represents a 25.38% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 20,165 shares of company stock valued at $2,680,993 over the last three months. 3.70% of the stock is owned by company insiders.
Palomar Stock Performance
PLMR stock opened at $130.09 on Friday. The company has a market capitalization of $3.42 billion, a P/E ratio of 17.49 and a beta of 0.40. The company has a 50-day simple moving average of $130.76 and a 200 day simple moving average of $123.92. Palomar Holdings, Inc. has a fifty-two week low of $100.81 and a fifty-two week high of $147.62. The company has a quick ratio of 0.50, a current ratio of 0.50 and a debt-to-equity ratio of 0.30.
Palomar (NASDAQ:PLMR – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $2.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.19 by $0.17. The firm had revenue of $314.42 million during the quarter, compared to analyst estimates of $621.52 million. Palomar had a net margin of 18.61% and a return on equity of 23.28%. During the same quarter in the prior year, the firm posted $1.76 EPS. Sell-side analysts predict that Palomar Holdings, Inc. will post 9.21 earnings per share for the current fiscal year.
Palomar Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 2nd. Investors of record on Wednesday, August 19th will be issued a dividend of $0.45 per share. The ex-dividend date of this dividend is Wednesday, August 19th. This represents a $1.80 annualized dividend and a yield of 1.4%. Palomar’s payout ratio is presently 24.19%.
Palomar Company Profile
Palomar Holdings, Inc (NASDAQ: PLMR) is a specialty insurance holding company focused on providing medical stop-loss coverage and related administrative services to self-funded employer health plans in the United States. The firm operates through two primary business segments—Medical Stop-Loss and Specialty Program Management—to deliver tailored risk protection and comprehensive program administration.
In its Medical Stop-Loss segment, Palomar underwrites excess and aggregate stop-loss policies designed to shield self-insured employers from catastrophic medical claims that exceed pre-determined retention levels.
Read More
- Five stocks we like better than Palomar
- Blueprint for a Boom: SEC Clears the Crypto Runway
- Ross Stores Just Flipped the Off-Price Retail Story After TJX’s Marmaxx Miss
- Advance Auto Parts Plunged, But Its Turnaround Is Still Working
- Is Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?
Want to see what other hedge funds are holding PLMR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Palomar Holdings, Inc. (NASDAQ:PLMR – Free Report).
Receive News & Ratings for Palomar Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palomar and related companies with MarketBeat.com's FREE daily email newsletter.
